Detoxification depot for β-amyloid peptides

Current Alzheimer Research

Volumn 5, Issue 1, 2008, Pages 26-32

  Sundaram, Ranjini K ^a   Kasinathan, Chinnaswamy ^a   Stein, Stanley ^a   Sundaram, Pazhani ^a  

^a Recombinant Technologies LLC   (United States)

Author keywords

A ; Alzheimer's disease; Amyloid; Detox gels; RI peptides

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; MACROGOL; PEPTIDE; RETRO INVERSO PEPTIDE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMNESIA; ARTICLE; BIOTINYLATION; DEGENERATIVE DISEASE; DETOX GEL; DISEASE COURSE; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; GEL; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING;

ALZHEIMER DISEASE; AMINO ACIDS; AMYLOID BETA-PROTEIN; BIOTINYLATION; DRUG IMPLANTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; HYDROGELS; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; POLYETHYLENE GLYCOLS; SORPTION DETOXIFICATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 42149118981     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720508783884684     Document Type: Article

References (19)

1. Younkin SG. The role of A β -42 in Alzheimer's disease. J Physiol Paris 92: 289-92 (1998).
2. Jarrett JT, Lansbury PT Jr. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73:1055-8 (1993).
3. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, and Ihara Y. Visualization of A beta -42 and A beta -40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta -42. Neuron 13: 45-53 (1994).
4. Hilbich C, Kisters-Woike B, Reed J, Masters CL, and Beyreuther K. Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease βA4 peptides. J Mol Biol 228: 460-473 (1992).
5. Gordon DJ, Sciarretta KL, and Meredith SC. Inhibition of β-amyloid (-40) fibrillogenesis and disassembly of β-amyloid(-40) fibrils by short β-amyloid congeners containing N-methyl amino acids at alternate residues. Biochemistry 40: 8247-8245 (2001).
6. Tjernberg LO, Naslund J, Lindqvist F, Johansson J, Karlström AR, Thyberg J, et al. Arrest of β-amyloid fibril formation by a pentapeptide ligand. J Biol Chem 271: 8545-8548 (1996).
7. Watanabe K, Segawa T, Nakamura K, Kodaka M, Konakara T and Okuno H. Identification of the molecular interaction site of amyloid β peptide by using a fluorescence assay. J Peptide Res 58: 3-42-346 (2001).
8. Zhang G, Leibowitz MJ, Sinko PJ and Stein S. Multiple Peptide Conjugates for binding b-amyloid plaques of Alzheimer's disease. Bioconjug Chem 14: 86-92 (2003).
9. Qiu B, Stefanos S, Ma J, Lalloo A, Perry BA, Leibowitz MJ, et al. A hydrogel prepared by in situ cross-linking of a thiol-containing polyethylene glycol based polymer: A new biomaterial for protein drug delivery. Biomaterials 24: 11-18 (2003).
10. Sundaram P, Tigelaar RE and Brandsma JL. Intracutaneous vaccination with the cottontail rabbit papillomavirus (CRPV) L1 gene protects against virus challenge. Vaccine 15: 664-671 (1997).
11. Gref R, Luck M, Quellec P, Marchand M, Dellacherie E and Harnisch S, et al. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption, Colloids Surf B Biointerfaces 18: 301-313 (2000).
12. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2 : 864-70 (1996).
13. Tjernberg LO, Lilliehook C, Callaway DJ, Naslund J, Hahne S, Thyberg J, et al. Controlling amyloid beta-peptide fibril formation with protease-stable ligands. J Biol Chem 272:12601-5(1997).
14. Strazielle N, Ghersi-Egea JF, Ghiso J, Dehouck MP, Frangione B, Patlack C, et al. In vitro evidence that β-amyloid peptide 1-40 diffuses across the blood-brain barrier and affects its permeability. J Neuropathol Exp Neurol 59: 29-38 (2000).
15. DeMattos RB, Bales KR, Cummins DJ, Paul SM and Holtzman DM. Brain to plasma - β amyloid efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295: 2264-2267 (2002).
16. Dickstein DL, Biron KE, Ujiioe M, Pfeifer PG, Jeffries AR and Jeffries WA. Aβ peptide immunization restores blood-brain barrier integrity. FASEB J. 20: 426-433 (2006).
17. Steinberg D. Companies halt first Alzheimer vaccine trial. Scientist 16:22 (2002).
18. Matsuoka Y, Saito M, LaFrancois J, Saito M, Gaynor K, Olm V, et al. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci 23: 29-33 (2003).
19. Matsuoka Y, Shao L, Debnath M, LaFrancois J, Becker A, Gray A, et al. An Aβ sequestration approach using non-antibody Aβ binding agents. Curr Alzheimer Res 2: 265-268 (2005).